Sugi Predict

Sugi Predict / Compounds / SCHEMBL4802860

SCHEMBL4802860

SCHEMBL4802860

Cc1nc(N)sc1-c1ccnc(Nc2ccc(N(C)C)cc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 19/20 1.00
▸ CDK4 P11802 14/20 1.00
▸ CCNE1 P24864 5/20 1.00
▸ CDK9 P50750 7/20 0.78
▸ AURKA O14965 6/20 0.78
▸ CDK1 P06493 6/20 0.78
▸ CDK7 P50613 6/20 0.78
▸ AURKB Q96GD4 5/20 0.78
▸ PLK1 P53350 3/20 0.74
▸ CCNT1 O60563 3/20 0.64
▸ ABL1 P00519 2/20 0.64
▸ GSK3B P49841 2/20 0.64
▸ CDK5 Q00535 2/20 0.64
▸ CDC7 O00311 1/20 0.64
▸ PLK4 O00444 1/20 0.64
▸ CIT O14578 1/20 0.64
▸ CHEK1 O14757 1/20 0.64
▸ GAK O14976 1/20 0.64
▸ EPHB6 O15197 1/20 0.64
▸ PDPK1 O15530 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799735 0.88 CDK2 (1.00) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL2073680 0.85 CDK2 (0.78) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL4799684 0.85 CDK2 (0.78) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL2076190 0.85 CDK2 (0.78) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL4797791 0.85 CDK2 (0.78) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL5052445 0.85 CDK2 (1.00) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL2283342 0.85 CDK2 (0.77) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL4802592 0.85 CDK2 (0.77) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL4801285 0.85 CDK2 (0.77) CDK2CDK4CCNE1CDK9AURKA
SCHEMBL16807900 0.85 CDK2 (0.73) CDK2CDK4CCNE1CDK9AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119909064-A Cystamine derivative or salt thereof and application thereof in preparation of medicines with antioxidation effect 北京大学深圳研究生院 2025-05-02 — — CN claimed
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-25 — — US claimed
CN-113852373-B Successive approximation type analog-to-digital converter with pipeline domino structure 西安电子科技大学 2024-07-12 — — CN claimed
CN-221036116-U Low-cost air conditioner control panel 骏升科技（扬州）有限公司 2024-05-28 — — CN claimed
US-11932850-B2 Cancer chemoprevention with STAT3 blockers Jill M. Siegfried, LLC (US) 2024-03-19 — — US claimed
CN-111384840-B Desk lamp power supply management circuit compatible with multiple voltage supplies and control method 浙江凯耀照明有限责任公司 2022-03-11 — — CN claimed
EP-1430051-B1 N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS CYCLACEL LTD (GB) 2006-12-27 — — EP claimed
US-20060199830-A1 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds CYCLACEL LIMITED (GB) 2006-09-07 — — US claimed
US-20050288307-A1 Anti-viral compounds CYCLACEL LIMITED (GB) 2005-12-29 — — US claimed
EP-1581231-A1 ANTI-VIRAL COMPOUNDS Cyclacel Limited (GB) 2005-10-05 — — EP claimed
US-20040259894-A1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds CYCLACEL LIMITED (GB) 2004-12-23 — — US claimed
EP-1430051-A1 N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS Cyclacel Limited (GB) 2004-06-23 — — EP claimed
WO-2004043467-A1 ANTI-VIRAL COMPOUNDS CYCLACEL LIMITED (GB) 2004-05-27 — — WO claimed
WO-2003029248-A1 N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS CYCLACEL LIMITED (GB) 2003-04-10 — — WO claimed
US-20260143965-A1 LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT SAMSUNG DISPLAY CO LTD (KR) 2026-05-21 — — US disclosed
US-12635537-B2 Interconnection structure for multi-chip interposer and method of manufacturing same TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2026-05-19 — — US disclosed
CN-115650982-B Compounds for imaging TAU protein aggregates AC免疫有限公司 2026-05-19 — — CN disclosed
EP-1430051-A1 N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS Cyclacel Limited (GB) 2004-06-23 — — EP disclosed
WO-2004043467-A1 ANTI-VIRAL COMPOUNDS CYCLACEL LIMITED (GB) 2004-05-27 — — WO disclosed
WO-2003029248-A1 N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS CYCLACEL LIMITED (GB) 2003-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259894-A1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds CDK4, CDK2, CDKL4 CDK2 2/4885CDK4 1/4885CCNE1 46/4885
US-20060199830-A1 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds CDK4, CDK2, CCNI CDK2 2/4885CDK4 1/4885CCNE1 44/4885
US-20260143965-A1 LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT NR2E3, NR2E1, NR0B2 CDK2 834/4885CDK4 1124/4885CCNE1 357/4885
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME NES, NFE2L2, NUCB2 CDK2 1219/4885CDK4 2213/4885CCNE1 1054/4885
US-12635537-B2 Interconnection structure for multi-chip interposer and method of manufacturing same CTCF, HTR3D, PIEZO1 CDK2 4217/4885CDK4 3035/4885CCNE1 4441/4885
US-11932850-B2 Cancer chemoprevention with STAT3 blockers STAT3, BCOR, GSTK1 CDK2 1651/4885CDK4 1239/4885CCNE1 3080/4885
US-20050288307-A1 Anti-viral compounds MAVS, HAVCR2, EIF2AK2 CDK2 205/4885CDK4 477/4885CCNE1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.